Business context and reporting period
The provided filing is Histogenics Corporation’s Form 10-Q for the quarter ended March 31, 2017, not an Ocugen, Inc. filing. Histogenics was a clinical-stage regenerative medicine company developing NeoCart, a cartilage-repair product candidate in a U.S. Phase 3 clinical trial under an FDA special protocol assessment. The interim financial statements are unaudited and presented under U.S. GAAP.
The company had not generated revenue from its planned principal operations and had never been profitable. As of May 8, 2017, it had 21.2 million common shares outstanding.
Financial results and key metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $4.5 million | $5.6 million | Down 19% |
| General and administrative expense | $2.3 million | $2.2 million | Up 5% |
| Total operating expenses | $6.8 million | $7.8 million | Down $1.0 million |
| Net loss | $7.1 million | $7.9 million | Improved $0.8 million |
| Loss attributable to common stockholders | $5.8 million | $7.9 million | Improved $2.1 million |
| Basic and diluted loss per share | $0.27 loss | $0.60 loss | Improved |
| Net cash used in operating activities | $7.3 million | $7.8 million | Improved $0.5 million |
| Cash and cash equivalents at period end | $16.4 million | $22.9 million | Down $6.5 million year over year |
| Cash, cash equivalents and marketable securities | $24.4 million | Not clearly provided | Not comparable from the filing text |
There is no meaningful operating margin because revenue was zero. The operating loss was $6.8 million, representing the company’s operating cash-burn and development investment.
Net cash used in investing activities was $8.0 million, primarily reflecting purchases of marketable securities. Financing cash use was $0.1 million, principally equipment-loan repayments. Total cash and cash equivalents decreased by $15.5 million during the quarter.
At March 31, 2017, total assets were $28.3 million, total liabilities were $21.3 million, and stockholders’ equity was $7.0 million. The warrant liability was $13.5 million, compared with $13.2 million at December 31, 2016. Equipment-loan borrowings totaled approximately $0.6 million, including $0.6 million classified as current, and the company reported compliance with its loan covenants.
Material changes versus the prior comparable period
- Research and development expense declined by $1.1 million, mainly because of lower consulting and temporary labor costs and lower patient-recruiting expenses.
- General and administrative expense increased by $0.1 million, primarily due to higher stock-based compensation and repairs and maintenance costs.
- Net loss improved by $0.8 million, although other expense increased because of a $0.3 million unfavorable change in the fair value of the warrant liability.
- Stock-based compensation increased to $0.5 million from $0.3 million.
- Cash used in investing activities increased substantially because the company invested $8.0 million in marketable securities during the quarter; the company had held no available-for-sale securities before Q1 2017.
- Shares used in the loss-per-share calculation increased to 21.9 million from 13.3 million, reflecting equity issued in connection with the September 2016 private placement and related securities.
Guidance, outlook, risks and unusual items
Management expected continuing net losses for the next several years and stated that additional capital would be required to complete a Biologics License Application for NeoCart, commercialize the product if approved, and advance other candidates. Based on current development plans, the company expected its $24.4 million of cash, cash equivalents and marketable securities to fund operations into the middle of 2018. No committed source of additional capital existed. Cost-reduction and deferral measures could extend funding into the third quarter of 2018.
- NeoCart remained dependent on successful Phase 3 enrollment and completion, manufacturing scale-up, FDA review and eventual market acceptance.
- The company’s previous enrollment guidance had shifted from June 2016 to June 2017 because enrollment trends had not met expectations.
- FDA acceptance of the comparability of transferred raw materials and manufacturing processes remained a significant execution risk and could require additional studies, delay the trial or delay commercialization.
- The company depended on additional equity, debt, strategic transactions or partnerships. New financing could be unavailable, costly, dilutive or subject to restrictive covenants.
- The September 2016 private placement generated approximately $27.6 million of net proceeds and included Series A preferred stock convertible into approximately 10.7 million common shares and warrants for approximately 13.5 million common shares. These securities create potential dilution and contributed to the large warrant liability.
- Future contingent commitments included regulatory and commercial milestones, royalties under license agreements, and up to $12 million of commercialization milestones plus $22.5 million of sales milestones under the Intrexon collaboration agreement.
- Management reported no material pending legal proceedings and stated that disclosure controls and procedures were effective as of March 31, 2017.
- An April 2017 lease amendment extended the Waltham facility lease commencement to January 1, 2018, with termination on December 31, 2024 and a five-year renewal option.
Most important facts for investors to verify
- Verify the issuer identity: the supplied filing is for Histogenics Corporation, while the request identifies Ocugen, Inc.
- Verify current cash runway and the timing, size and terms of required future financing.
- Track NeoCart Phase 3 enrollment, trial completion, manufacturing comparability, FDA interactions and the timing of any BLA filing.
- Assess potential dilution from Series A preferred stock, approximately 13.6 million outstanding warrants and equity compensation awards.
- Review the valuation methodology and volatility of the $13.5 million Level 3 warrant liability, which affected reported earnings.
- Review contingent milestone, royalty, lease and collaboration obligations, particularly those involving Intrexon and licensed technologies.